KROS: Keros Therapeutics Inc

KROS新闻

• 15:41 KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment
• 15:36 KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026?
• 15:29 KROS Rinvatercept: What to Know Before DMD Phase II Starts
• 15:30 Why Is Keros Therapeutics (KROS) Up 2.5% Since Last Earnings Report?
• 06:46 Insmed (INSM) Soars 5.5%: Is Further Upside Left in the Stock?
• 17:18 KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026
• 17:18 KROS Stock: What to Know About Rinvatercept in DMD
• 17:18 KROS: Is the Discount Book Value a Value Trap?
• 16:57 Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market?
• 17:53 Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline?
• 22:10 Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates
• 21:23 KerosQ1每股收益及营收逊于预期
• 21:23 Keros earnings missed by $0.16, revenue fell short of estimates
• 21:15 Keros Therapeutics任命前Lyell首席财务官加入董事会
• 14:39 Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings?
• 16:39 Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?
• 15:50 SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD
• 14:16 Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside?
• 14:15 Is KROS' KER-065 the Next Breakthrough in DMD Space?
• 12:18 JANX Enters Global Oncology Collaboration With BMY, Stock Rises
• 16:55 Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema
• 13:36 MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know
• 17:53 Novartis' Ianalumab Wins Breakthrough Therapy Tag for Sjogren's Disease
• 16:15 Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia